)
Sartorius (SRT) investor relations material
Sartorius Investor update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Webinar focus
Webinar on AI-powered cell engineering, virtual cell modeling and improving biomanufacturing yields, held Nov. 18, 2026.
Virtual cell models can predict responses to molecular, genetic and process changes, supporting earlier development decisions.
AI and machine learning can identify high-producing CHO clones in days instead of weeks.
Applications and expected benefits
Applications span T-cell expansion, CHO cell productivity, product quality and process optimization.
Predictive, model-guided approaches can shorten development timelines, reduce risk and support stable, scalable, reproducible processes from cell engineering through commercial-scale manufacturing.
- 9M growth, higher cash flow and lower leverage supported FY guidance.SRT
Q3 2026 - Sales and margins rose in H1 2026, with guidance confirmed despite tariff impacts.SRT
Q2 2026 - Sales up 7.5% in Q1 2026, resilient margins, and 2026 guidance confirmed amid volatility.SRT
Q1 2026 - Midterm targets: 8%-11% organic growth, margin expansion, and innovation-led portfolio focus.SRT
CMD 2026 - Strong sales and margin gains in 2025 support a positive outlook for 2026.SRT
Q4 2025 - Profitable growth with 7.5% sales increase, higher EBITDA margin, and raised guidance.SRT
Q3 2025 - Strong H1 2025 growth driven by recurring consumables and margin expansion; outlook reaffirmed.SRT
Q2 2025 - Order intake and cash flow rose, supporting stable sales and margins for 2024.SRT
Q3 2024 - 2024 sales and profitability held firm; strong Q4 and order recovery signal cautious optimism for 2025.SRT
Q4 2024
)
)
)
)
)
)
)
)